Clinical Trial Update: Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan [Phase 3]

View source ↗

Summary

Ono Pharmaceutical's ONO-5920 completed a Phase 3 controlled trial in patients with involutional osteoporosis in Japan.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• ONO-5920

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Involutional Osteoporosis | Phase 3 | Status: COMPLETED